Sustivaa (Efavirenz) Receives Us Fda Snda Approval For Use In HIV-1 Infected Pediatric Patients

... is a risk of developing HIV resistance if SUSTIVA is underdosed. Bristol-Myers Squibb remains at the forefront of HIV/AIDS research and continues to pursue the development of treatment options for children and adults with HIV. Studies are ongoing ...

http://www.medicalnewstoday.com/releases/260219.php